Effect of Antiglaucoma Agents on Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection
Information source: Mashhad University of Medical Sciences
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Intraocular Pressure Change in Intravitreal Injection
Intervention: Timolol (Drug); Brimonidine (Drug); Acetazolamide (Drug); Mannitol (Drug); Placebo (Drug)
Phase: N/A
Status: Completed
Sponsored by: Mashhad University of Medical Sciences Official(s) and/or principal investigator(s):
Nasser Shoeibi, M.D., Principal Investigator, Affiliation: Retina Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Summary
To assess the effect of prophylactic antiglaucoma agents in prevention of acute intraocular
pressure rise after intravitreal injection.
Clinical Details
Official title: Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection: the Effect of Pretreatment With Antiglaucoma Agents
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Primary outcome: change in IOP
Detailed description:
Acute intraocular pressure elevation after intravitreal injection of bevacizumab was
proven. Acute intraocular pressure elevation most probably is volume related and long term
intraocular pressure elevation relates to pharmacologic features of the medications which
results in anatomic changes in the angle of anterior chamber. Numerous studies found an
intraocular pressure elevation right after the injection and quick normalization within
maximally 30 minutes. This intraocular pressure elevation which lasts about 30 minutes, can
result in irreversible visual loss especially in patients with critical remaining nerve
fibers in the optic nerve head, as occurs in glaucomatous patients. Is there any way to
prevent or even shorten this time of intraocular pressure elevation? We tried in our study
to find a suitable response for a question above, so we used several anti-glaucoma agents
(Timolol, Brimonidine, Acetazolamide, Mannitol versus placebo) as a prophylaxis to prevent
acute intraocular pressure elevation right after intravitreal bevacizumab injection.
Eligibility
Minimum age: 40 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- all patients who candidate for receiving intravitreal bevacizumab
Exclusion Criteria:
- patients who had advanced glaucoma
- patients who received antiglaucoma agents in the past
- patients who had corneal scar which affect IOP measurement
Locations and Contacts
Retina Research Center, Khatam eye Hospital, Mashhad, Khorasan Razavi, Iran, Islamic Republic of
Additional Information
Starting date: February 2012
Last updated: May 13, 2014
|
